Shareholding disclosure

Cosmo Pharmaceuticals NV

Declared position

46.56%

Threshold

Crossed upwards

Timeline

Published

17.12.2020

Transaction

01.07.2016

Transfer date

01.07.2016

Voting rights breakdown

Voting rights acquired46.56%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAKCF00074

Beneficial owner

Cosmo Pharmaceuticals NV

Declared address

Cosmo Pharmaceuticals N.V., Dublin 2

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Cosmo Pharmaceuticals NV

Cassiopea S.p.A.17.12.2020TAKCF00074

Disclosure summary

Cosmo Pharmaceuticals NV disclosed a holding in Cassiopea S.p.A. on the acquisition side, published by SIX Exchange Regulation on 17.12.2020, at 46.56% of voting rights. Notice category: Single shareholder.

Disclosed position

46.56%

Voting rights acquired

Voting rights acquired46.56%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Cosmo Pharmaceuticals NV disclosed a holding in Cassiopea S.p.A., published on 17.12.2020.

Publication date17.12.2020

Transaction date01.07.2016

Transfer date01.07.2016

Issuing companyCassiopea S.p.A.

Beneficial ownerCosmo Pharmaceuticals NV

Declared addressCosmo Pharmaceuticals N.V., Dublin 2

CategorySingle shareholder

Voting rights acquired46.56%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAKCF00074

Source: SIX Exchange Regulation · Publication date: 17.12.2020

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open